Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014, Article ID 502174, 6 pages
http://dx.doi.org/10.1155/2014/502174
Clinical Study

Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related Macular Degeneration

Department of Ophthalmology, University of Florida College of Medicine, 580 West 8th Street, Tower 2, Jacksonville, FL 32209, USA

Received 24 April 2014; Revised 3 June 2014; Accepted 9 June 2014; Published 10 July 2014

Academic Editor: Siamak Ansari-Shahrezaei

Copyright © 2014 Kakarla V. Chalam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Congdon, B. O'Colmain, C. C. Klaver et al., “Causes and prevalence of visual impairment among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 477–485, 2004. View at Publisher · View at Google Scholar
  2. J. Seddon and C. Chen, “The epidemiology of age related macular degeneration,” in Controversies and Advancement in the Treatment of Retinal Disease, J. Heier, Ed., pp. 17–39, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2004. View at Google Scholar
  3. W. R. Green, “Histopathology of age-related macular degeneration,” Molecular Vision, vol. 5, pp. 27–36, 1999. View at Google Scholar · View at Scopus
  4. E. J. Duh, H. S. Yang, J. A. Haller et al., “Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis,” American Journal of Ophthalmology, vol. 137, no. 4, pp. 668–674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Kijlstra, E. C. La Heij, and F. Hendrikse, “Immunological factors in the pathogenesis and treatment of age-related macular degeneration,” Ocular Immunology and Inflammation, vol. 13, no. 1, pp. 3–11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kvanta, P. V. Algvere, L. Berglin, and S. Seregard, “Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor,” Investigative Ophthalmology and Visual Science, vol. 37, no. 9, pp. 1929–1934, 1996. View at Google Scholar · View at Scopus
  11. T. Cohen, D. Nahari, L. W. Cerem, G. Neufeld, and B. Z. Levin, “Interleukin 6 induces the expression of vascular endothelial growth factor,” The Journal of Biological Chemistry, vol. 271, no. 2, pp. 736–741, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Saidi, M. Hagedorn, N. Allain et al., “Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness,” International Journal of Cancer, vol. 125, no. 5, pp. 1054–1064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Seddon, S. George, B. Rosner, and N. Rifai, “Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers,” Archives of Ophthalmology, vol. 123, no. 6, pp. 774–782, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. K. Sharma, A. T. Rogojina, and K. V. Chalam, “Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF,” Molecular Vision, vol. 16, pp. 2175–2184, 2010. View at Google Scholar · View at Scopus
  15. K. V. Chalam, S. Balaiya, and R. K. Murthy, “Accurate estimation of vascular endothelial growth factor levels in microsamples with a low-cost bead-based assay,” Retina, vol. 30, no. 5, pp. 815–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Noma, H. Funatsu, M. Yamasaki et al., “Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion,” Eye, vol. 22, no. 1, pp. 42–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. I. Roh, S. J. Lim, J. M. Ahn, J. B. Lim, and O. W. Kwon, “Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 5, pp. 635–640, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Funk, G. Schmidinger, N. Maar et al., “Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab,” Retina, vol. 30, no. 9, pp. 1412–1419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. I. Roh, H. S. Kim, J. H. Song, J. B. Lim, H. J. Koh, and O. W. Kwon, “Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed cnv associated with amd after bevacizumab treatment,” Retina, vol. 29, no. 4, pp. 523–529, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. P. A. Keane, S. Liakopoulos, K. T. Chang et al., “Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration,” Ophthalmology, vol. 115, no. 12, pp. 2206–2214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Golbaz, C. Ahlers, G. Stock et al., “Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy,” Investigative Ophthalmology & Visual Science, vol. 52, no. 3, pp. 1599–1605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Browning, C. M. Fraser, and B. W. Propst, “The variation in optical coherence tomography-measured macular thickness in diabetic eyes without clinical macular edema,” The American Journal of Ophthalmology, vol. 145, no. 5, pp. 889–893, 2008. View at Publisher · View at Google Scholar · View at Scopus